• Careers
  • Contact
Intensity Therapeutics
Intensity Therapeutics
  • Home
  • Company
    • Introduction
    • Senior Management Team
    • Board of Directors
    • Scientific Advisors
  • Clinical Research
    • Overview
    • FAQs
    • For Patients
  • Technology
    • DfuseRx℠ Product Discovery Technology
    • Pipeline
    • Lead Product: INT230-6
    • Mechanism of Action
    • Intellectual Property and Patents
  • Partnerships
  • News & Events
    • Press Releases
    • Events and Presentations
    • Intensity Therapeutics in the News
    • Publications, Papers and Posters
  • Investors
Intensity Therapeutics
  • Home
  • Company
    • Introduction
    • Senior Management Team
    • Board of Directors
    • Scientific Advisors
  • Clinical Research
    • Overview
    • FAQs
    • For Patients
  • Technology
    • DfuseRx℠ Product Discovery Technology
    • Pipeline
    • Lead Product: INT230-6
    • Mechanism of Action
    • Intellectual Property and Patents
  • Partnerships
  • News & Events
    • Press Releases
    • Events and Presentations
    • Intensity Therapeutics in the News
    • Publications, Papers and Posters
  • Investors
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financials
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Events & Presentations
  • Email Alerts
Mar 08, 2016 7:30am EST

Intensity Therapeutics Selected to Present at BioCentury Future Leaders Conference

Mar 03, 2016 7:35am EST

Intensity Therapeutics Reports anti-Cancer Immunological Effect Generated by INT230-6

Nov 05, 2015 7:35am EST

Intensity Therapeutics Preclinical Results Show Anti-Cancer Synergy of INT230-6 with Anti-PD-1 Compounds

Oct 22, 2015 7:35am EDT

Intensity Therapeutics Forms Scientific Advisory Board Comprised of World-Leading Oncologists and Scientists

Apr 16, 2015 7:36am EDT

Intensity Therapeutics, Inc.’s Research Selected for Presentation at the 2015 American Association for Cancer Research Annual Meeting

Oct 09, 2014 7:30am EDT

Intensity Therapeutics, Inc.’s Research Selected for Presentation at the Annual National Cancer Institute Cancer Immunology and Immunotherapy Conference

Sep 03, 2014 7:36am EDT

Intensity Therapeutics, Inc. Appoints Ian B. Walters M.D., MBA as Vice President and Chief Medical Officer

May 28, 2014 7:33am EDT

Intensity Therapeutics, Inc. Awarded Cooperative Research and Development Agreement from the National Cancer Institute

  • arrow_back
  • 1…
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Privacy Policy
Menu
  • Privacy Policy

© 2025 Intensity Therapeutics. All rights reserved.

Linkedin Twitter